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Abstract
AIM: IBD is a systemic disease associated with a large
number of extraintestinal manifestations (EIMs). Our aim
was to determine the prevalence of EIMs in a large IBD
cohort in Veszprem Province in a 25-year follow-up study.
METHODS: Eight hundred and seventy-three IBD patients
were enrolled (ulcerative colitis/UC/: 619, m/f: 317/302,
mean age at presentation: 38.3 years, average disease
duration: 11.2 years; Crohn’s disease/CD/: 254, m/f: 125/129,
mean age at presentation: 32.5 years, average disease
duration: 9.2 years). Intestinal, extraintestinal signs and
laboratory tests were monitored regularly. Any alteration
suggesting an EIMs was investigated by a specialist.
RESULTS: A total of 21.3 % of patients with IBD had EIM
(UC: 15.0 %, CD: 36.6 %). Age at presentation did not affect
the likelihood of EIM. Prevalence of EIMs was higher in women
and in CD, ocular complications and primary sclerosing
cholangitis (PSC) were more frequent in UC. In UC there was
an increased tendency of EIM in patients with a more extensive
disease. Joint complications were more frequent in CD
(22.4 % vs UC 10.2 %, P<0.01). In UC positive family history
increased the risk of joint complications (OR:3.63). In CD the
frequency of type-1 peripheral arthritis was increased in
patients with penetrating disease (P=0.028). PSC was present
in 1.6 % in UC and 0.8 % in CD. Dermatological complications
were present in 3.8 % in UC and 10.2 % in CD, the rate of
ocular complications was around 3 % in both diseases. Rare
complications were glomerulonephritis, autoimmune hemolytic
anaemia and celiac disease.
CONCLUSION: Prevalence of EIM in Hungarian IBD patients
is in concordance with data from Western countries. The
high number of EIM supports a role for complex follow-up
in these patients.
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INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic
inflammatory diseases of undetermined origin. Inflammatory
bowel disease (IBD) is a multifactorial polygenic disease with
probable genetic heterogeneity. In this hypothesis, the disease
may develop in a genetically predisposed host as a consequence
of altered mucosal barrier and disregulated immune response
to environmental, in particular enteric antigens, resulting in
continuous immune-mediated inflammation [1-4].  IBD
predominantly affects the gastrointestinal system but it is
associated with a large number of extraintestinal manifestations
(EIMs)[5]. Some disorders parallel the activity of the bowel
disease but for a number of these conditions, their courses run
independently of the course of the intestinal disease[6,7].
Furthermore, there has been some variance in the literature as
to whether these EIMs are more associated with CD or UC. In
the classical study of Greenstein et al.[8] EIMs were classified
as colitis associated, small bowel associated and none specific
manifestations.
     EIMs contribute significantly to morbidity and mortality.
Defining specific associations of immune mediated diseases
in extraintestinal sites and IBD may be helpful in the better
understanding of the pathogenesis of IBD.
     The pathogenesis of EIMs is also multifactorial. The role
of genetic factors is supported by family and candidate (e.g.
certain HLA) gene studies[9-11]. The role of humoral immunity
is supported by the higher prevalence of autoantibodies in the
presence of EIMs, especially pANCA in primary sclerosing
cholangitis (PSC). The immunological and clinical connections
between these diseases and IBD have never been fully
elucidated.
      In this study we aimed to define the prevalence of EIMs in
a 25-year follow up study in Hungarian IBD patients. We
sought to determine if any of the EIMs was more likely
associated with CD or UC, with male or female gender in a
follow-up study. Possible associations between EIMs and
location and disease behaviour were also investigated.
MATERIALS AND METHODS
Eight hundred and seventy-three IBD patients followed-up at
the Out- and Inpatient Gastroenterology Units of the Csolnoky
F. Province Hospital in Veszprem Province were enrolled. This
hospital is the secondary referral center for IBD patients in the
province.
     The data of the 619 UC patients (male/female: 317/302)
are summarized in Table 1. The age at presentation varied
between 9 and 80 years (average: 38.3 years). Average disease
duration was 11.2 years (1-56 years). The location of UC
according to the known greatest extent was proctitis in 117,
left sided colitis in 304 (including 171 patients with
proctosigmoiditis), subtotal (98) and pancolitis (100) in 198
cases. Two hundred and fifty-four CD patients were included
(125 males, 129 females). Average age at presentation was
32.5 years (12-80 years). According to the Vienna classification
192 patients were classified as A1, while 62 as A2. Disease
duration was 9.2 years (1-40 years). Location of CD was ileal
(L1) in 60, colonic (L2) in 81 and ileocolonic (L3) in 113
cases. Patients with upper GI manifestation had lower GI
disease as well and they were classified according to their lower
GI disease. According to the disease behavior 83 of our CD
patients were defined as non-stricturing non-penetrating, 62
as stricturing and 105 as penetrating. Fifty-eight patients of
the 95 penetrating cases had parallel strictures. Patients with
indeterminate colitis were excluded.
Table 1  Clinical data of IBD patients
   Ulcerative colitis    Crohn’s disease
Number of patients    619     254
Male/female    317/302     125/129
Mean age at diagnosis    38.3 yrs (9-80 yrs)     32.5 yrs (12-80 yrs)
Location    Proctitis: 117     L1: 60
   Left sided colitis: 304     L2: 81
   Pancolitis: 198     L3: 113
Behaviour of CD    -     B1: 87
    B2: 62
    B3: 105
In Crohn’s disease (CD). Location: L1: terminal ileum, L2:
colonic, L3: ileocolonic, behaviour: B1: non stricturing-non
penetrating, B2: stricturing, B3: penetrating.
    Patients in remission were followed-up twice per year.
Patients who relapsed were followed-up or hospitalised
according to the actual disease activity. Special interest was
dedicated to the presence of EIM. Screening of EIMs was not
performed, therefore the number of EIMs may have been
underestimated. Routine follow-up consisted of assessment of
patient’s complaints, physical examination and laboratory
testing.
     Any alteration suggesting an EIMs was investigated by a
specialist. In this study we did not assess the association
between disease activity and the presence of EIM. Major EIMs
studied in this report were axial and peripheral arthropathies
(including ankylosing spondylitis), aseptic femoral head
necrosis, primary sclerosing cholangitis (PSC), small duct
cholangitis, autoimmune hepatitis, erythema nodosum,
pyoderma gangrenosum, chronic urticaria, acute anterior
uveitis, iritis, episcleritis, conjunctivitis, autoimmune hemolytic
anaemia (AIHA), immune thrombocytopenic purpura (ITP),
celiac disease, myositis, and glomerulonephritis.
     Joint involvements were classified as peripheral and/or axial
arthropathies. Peripheral arthropathies were divided into two
subgroups according to the classification of Orchard et al[13].
Type-1 arthritis is an acute self-limiting pauciarticular (less
than 5 joints) arthropathy typically affecting large joints. It is
associated with other EIMs and its course parallels with the
activity of the bowel disease. In contrast, type 2 arthritis is a
chronic bilateral, symmetrical polyarticular arthropathy
affecting five or more small joints. Its course runs independently
of the course of the intestinal disease. Axial arthropathies
are divided into sacroileitis and ankylosing spondylitis (SPA).
Its incidence is 20-times higher than that in the normal
population[14]. Rheumatologists investigated sacroileitis and
ankylosing spondylitis cases. Laboratory testing (rheumatoid
factor), X-ray and since 1997 MRI examinations were done.
   Patients with elevated liver function tests (LFT,
aminotransferases, cholestatic enzymes) were followed-up
more cautiously. In patients with chronic or progressive
elevation of enzyme levels liver biopsy and/or endoscopic
retrograde cholangiopancreatography (ERCP) examination
was done if patient gave informed consent. The diagnosis of
PSC was based on elevated liver function tests, ERCP and
consistent histology findings. Small duct PSC was diagnosed
if histology suggested PSC, but ERCP could not verify the
diagnosis[15,16]. Cholelithiasis, cirrhosis and focal nodular
hyperplasia (FNH) were excluded from hepatobiliary
manifestations.
     In patients with verified thrombosis, blood samples were
examined for hypercoagulability including in almost all cases
analysis of plasminogen, proteins C and S activity and factor
V Leiden mutation.
    Patients with glomerulonephritis were followed-up by
nephrologists as well. Diagnosis was based on clinical and
chemical data and congruent histology findings. Ureteral
obstruction was diagnosed by cystoscopy and urography, CT
or MRI. If the alteration suggested fistulae in the urinary tract,
cytography was also performed.
Statistical analysis
For statistical comparison of the data, Statistica 6.0 (Statsoft
Inc, USA) was used. Normality was tested by Shapiro-Wilk’s
W test. c2 test with Yates correction was used to compare
groups and odds ratios were calculated.
RESULTS
The prevalence of major (joint, hepatobiliary, ocular and
cutaneous) and all EIMs determined in this study are shown in
Table 2. Major EIMs were apparent more frequently in CD
than in UC (36.6 % vs 15.0 %, P<0.001). EIMs were more
frequent in patients with a disease duration for more than
10 years in both CD (22.1 % vs 48.9 %, P=0.003) and UC
(22.1 % vs 10.4 %, P<0.001).
Table 2  Prevalence of extraintestinal manifestations (EIM)
in IBD
Disease duration
  Total n (%)
 10 yrs n (%)           > 10 yrs n (%)
IBD    873     511 352
Major EIMs    186 (21.3)       86 (16.8) 102 (30.0)
All EIM signs    547 (62.7)     278 (54.4) 269 (76.4)
Ulcerative colitis   619     357 262
Major EIMs      93 (15.0)       37 (10.4)   58 (22.1)
All EIM signs    360 (58.2)     167 (46.8) 193 (73.7)
Crohn’s disease   254     164   90
Major EIMs      93 (36.6)       49 (29.9)   44 (48.9)
All EIM signs    187 (73.6)     111 (67.7)   76 (84.4)
     The prevalence of EIMs was higher in CD except ocular
complications and PSC (P<0.001 for joint, hepatobiliary and
cutaneous manifestations, Tables 3 and 4). In general, EIMs
were more frequent in women except hepatobiliary
manifestations and arthropathies in UC patients.
     All major EIMs were more prevalent in more extensive
UC (Table 5). There was a tendency of increased frequency of
joint manifestations in CD patients with colonic involvement
(L2 and L3: 23.7 %) compared to patients with only ileal
disease (18.3 %, P=NS, Table 5). The prevalences of
hepatobiliary, ocular and cutaneous manifestations were not
different according to disease location.
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Table 3  Age at presentation and prevalence of major extraintestinal
manifestations in patients with IBD
A1 n (%) A2 n (%)
UC (n: 619) 369  250
Joint   32 (8.7)  20 (8.0)
Hepatobiliary   49 (13.3)  28 (11.2)
Cutaneous   17 (4.6)    7 (2.8)
Ocular   11 (3.0)    8 (3.0)
CD (n: 254) 192  62
Joint   48 (25.0)    9 (14.5)
Hepatobiliary   48 (25.0)    9 (14.5)
Cutaneous   20 (10.4)    6 (9.7)
Ocular     5 (2.6)    3 (4.8)
A1: age at presentation <40 yrs, A2: age at presentation 40 yrs.
Table 4A  Familial IBD and association with extraintestinal
manifestations
       Total      First degree           Second degree
          relative                 relative
Ulcerative colitis      24/619 18 (14 UC+4 CD)       6 (5 UC+1 CD)
        (3.9 %)           (2.9 %)    (1.0%)
Crohn’s disease        31/254 20 (3 UC+17 CD)     11 (2 UC+9 CD)
       (12.2 %)                 (7.9%)    (4.3%)
Table 4B  Familial IBD and association with extraintestinal
manifestations
         Ulcerative colitis          Familial IBD
Number of patients 619 24
Joint   52 (8.4 %)   6 (25.0 %)
Hepatobiliary   77 (12.4 %)   3 (12.5 %)
Cutaneous   24 (3.9 %)   1 (4.2 %)
Ocular   19 (3.0 %)   2 (8.3 %)
            Crohn’s disease           Familial IBD
Number of patients 254 31
Joint   57 (22.4 %) 11 (35.5 %)
Hepatobiliary   57 (22.4 %)   4 (12.9 %)
Cutaneous   26 (10.2 %)   2 (6.5 %)
Ocular     8 (3.1%)   0
Table 5  Prevalence of extraintestinal manifestations in ulcer-
ative colitis and Crohn’s disease according to location and
disease behaviour
   Joint          Hepatobiliary     Cutaneous       Ocular
   n (%)                  n (%)   n (%)            n (%)
Location Ulcerative colitis
Proctitis   5 (4.3)   9 (7.7)   1 (0.9)            1 (0.9)
(n=117)
Left sided 14 (4.6) 32 (15.7)   8 (2.6)            7 (2.3)
colitis (n=304)
Pancolitis 33 (16.7) 36 (18.2) 15 (7.6)          12 (6.1)
(n=198)
Location Crohn’s disease
L1 (n=60) 11 (18.3) 14 (23.3)   6 (10.0)          2 (3.3)
L2 (n=81) 17 (21.0) 17 (21.0) 10 (12.3)          3 (3.7)
L3 (n=113) 29 (25.7) 26 (23.0) 10 (8.8)            3 (2.7)
Behaviour
B1 (n=87) 13 (14.9) 22 (25.3) 11 (12.6)          1 (1.1)
B2 (n=62) 16 (25.8) 11 (17.7)   5 (8.1)             0
B3 (n=105) 28 (27.6) 24 (22.9) 10 (9.5)            7 (6.7)
    Age at presentation (A1: <40 years, A2: =40 years) did
slightly affect the prevalence of EIMs (Table 3). Joint
manifestations were more prevalent in CD patients with earlier
disease onset (OR: 1.96, 95 % CI: 1.01-4.21). The same
tendency was observed for cutaneous manifestations.
      Familial disease was seen in 3.9 % of patients with UC and
12.2 % of patients with CD (Tables 4A-B). Joint manifestations
were more frequent in UC patients with familial disease (OR:
3.63, 95 % CI: 1.43-9.31) than without. The same tendency
was seen in UC patients (OR: 1.9, 95 % CI: 0.87-4.14) and
ocular manifestations were found in familial UC cases.
Table 6A  Joint manifestations in IBD patients
        Total  Axial             Type-1        Type-2
        n (%)          arthritis            arthritis        arthritis
  n (%)               n (%)         n (%)
Ulcerative colitis
Total (n=619)       52 (8.4) 20 (3.2)             17 (2.7)        13 (2.1)
Male (n=317)       24 (7.6) 10 (3.2)               7 (2.2)          7 (2.2)
Female (n=302)       28 (9.3)* 10 (3.4)             10 (3.3)          6 (2.0)
Crohn’s disease
Total (n=254)       57 (22.4) 26 (10.2)           29 (11.4)          8 (3.1)
Male (n=125)       23 (18.4) 11 (8.8)             12 (9.6)          3 (2.4)
Female (n=129)       34 (26.4) 15 (11.6)           17 (13.2)          5 (3.9)
*Two female patients with ulcerative colitis had rheumatoid
arthritis.
Table 6B  Joint manifestations in IBD according to location
and disease behaviour
  Total          Axial  Type-1       Type-2
  n (%)        arthritis       arthritis     arthritis
          n (%)    n (%)         n (%)
Location           Ulcerative colitis
Proctitis (n=117)   5 (4.3)*         1 (0.9)          2 (1.8)        1 (0.9)
Left sided colitis 14 (4.6)           4 (1.3)          5 (1.6)        5 (1.6)
(n=304)
Pancolitis (n=198) 33 (16.7)*      15 (7.6)        10 (5.0)        7 (3.5)
Location            Crohn’s disease
L1 (n=60) 11 (18.3)         5 (8.3)    4 (6.7)       2 (3.3)
L2 (n=81) 17 (21.0)         7 (8.6)        10 (12.3)      3 (3.7)
L3 (n=113) 29 (25.7)       14 (12.4)      15 (13.3)      3 (2.7)
Behaviour
B1 (n=87) 13 (14.9)         8 (9.2)   5 (5.7)        2 (2.3)
B2 (n=62) 16 (25.8)         8 (12.9)   6 (9.7)        3 (4.8)
B3 (n=105) 28 (27.6)       10 (9.5) 18 (17.1)       3 (2.9)
*One patient with proctitis and one with pancolitis had rheu-
matoid athritis.
     Joint manifestations were more frequent in CD than in
UC (P<0.001, Tables 6A-B.). There was a tendency of
increased frequency of joint manifestations in women with
CD (26.4 % vs 18.4 %, OR: 1.58, 95 % CI: 0.87-2.87). Axial
arthritis (10.2 % vs 3.2 %, P=0.0001) and type 1(11.4 % vs
2.7 %, P=0.0001) arthritis were more frequent in CD, with
equal prevalence of type-2 arthritis. In UC joint manifestations
were almost three-fold more frequent in patients with pancolitis
compared to proctitis and left sided colitis cases (P<0.002 for
both, Table 5). In CD a tendency of increased frequency of
joint manifestations was observed in patients with colonic
involvement (L2 and L3: 23.7 %) or stricturing/penetrating
disease (26.3 %) compared to patients with ileal only disease
(18.3 %) or non-stricturing non-penetrating disease behavior
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(14.9 %, Table 6B). An increased frequency of type 1 arthritis
was observed in patients with penetrating compared to non-
stricturing non-penetrating disease (P=0.028), the same
tendency was observed in patients with or without colonic
involvement. Type-1 arthritis affected more frequently the
joints of the lower extremities (most frequently the knee and
ankle), while type-2 arthritis was more common in the joints
of the upper extremities.
     Hepatobiliary manifestations are summerised in Table 7.
PSC was diagnosed in 10 patients with UC and only 2 patients
with CD. Small duct PSC was diagnosed in 8 and 6 cases,
respectively. Non-alcoholic fatty liver disease (NAFLD) or
non-alcoholic steatohepatitis (NASH) was diagnosed in 9.4 %
of UC patients and 19.3 % of CD patients (P<0.0001). These
patients had unexplained abnormal liver function tests (viral
hepatitis, autoimmune, drug or alcohol induced disease,
extrahepatic obstruction excluded). Liver biopsy was performed
in 22/107 cases, which identified NAFLD or NASH in almost
all cases. US proved hepatomegaly in 13/107 (12.1 %).
Progression to cirrhosis was not observed in these patients
during follow-up.
Table 7  Hepatobiliary manifestations in IBD patients
      Total               PSC          Small duct       NAFLD/
       n (%)   n (%)        PSC n (%)  NASH n (%)
Ulcerative colitis
Total (n=619)     77* (12.4) 10 (1.6)            8 (1.3)       58 (9.4)
Male (n=317)     39 (12.3)   3 (1.0)            6 (1.9)       30 (9.5)
Female (n=302)     38* (12.6)   7 (2.3)            2 (0.7)       28 (9.3)
Crohn’s disease
Total (n=254)     57 (22.4)   2 (0.8)            6 (2.4)       49 (19.3)
Male (n=125)     27 (21.6)   2 (1.6)            6 (4.8)       19 (15.2)
Female (n=129)     30 (23.3)   0             0       30 (23.3)
*One female patient had autoimmune hepatitis. NAFLD: non-
alcoholic fatty liver disease, NASH: non-alcoholic steatohepatitis.
      Cutaneous manifestations were seen in 10.2 % of the patients
with CD and 3.9 % of the patients with UC (Tables 8A-B).
Cutaneous manifestations were more common in women in
both UC (male/female: 5.0 %/2.8 %) and CD (13.2 %/7.2 %,
OR: 1.95, 95 % CI: 0.85-4.48). Erythema nodosum and
pyoderma gangrenosum were the most frequent manifestations.
In UC cutaneous manifestations were more frequent in more
extensive disease (7.6 % in pancolitis vs 2.1 % in proctitis or
left sided colitis, P=0.002).
     Ocular manifestations were apparent in approximately
3.0 % of UC and CD patients (Table 9). The prevalence was
more frequent in women in both UC (P=0.009, OR: 4.37, 95 %
CI: 1.51-12.6) and CD (OR:3.0, 95 % CI=0.67-8). Conjunctivitis,
acute anterior uveitis and scleritis were the most frequent
manifestations. Ocular manifestations developed mostly during
the early years of the disease. In UC more than half of the
patients with ocular complication had pancolitis (6.1 % in
pancolitis vs 1.9 % in left sided colitis or proctitis, P=0.01).
      Iron deficiency anaemia was seen in 35.8 % of CD patients
and in one fourth of UC patients (Tables 10A-C). It was more
frequent in women in UC (32.1 % vs 19.6 %, P<0.001, OR=1.95,
95 % CI: 1.35-2.81). Chronic anaemia was more frequent in
patients with CD (9.6 % vs 17.7 %, P<0.001). The prevalence of
macrocytic anaemia was around 4 % in both diseases. It was also
observed more frequently in patients with ileocolonic disease
than without it (P=0.03). The same tendency was observed
according to disease behaviour; chronic anaemia tended to be
more frequent in patients with stricturing or penetrating disease
(P=0.06, Table 10C). AIHA developed in four UC patients.
Table 8A  Cutaneous manifestations in patients with ulcer-
ative colitis (n=619)
Total Male       Female
 n (%) n (%)         n (%)
Erythema nodosum 8 (1.3) 2 (0.6)         6 (2.0)
Pyoderma gangrenosum 3 (0.5) 1 (0.3)         2 (0.6)
Chronic urticaria 6 (1.0) 2 (0.6)         4 (1.3)
Psoriasis 3 (0.5) 2 (0.6)         1 (0.3)
Aphthous stomatitis 3 (0.5) 1 (0.3)         2 (0.6)
Herpes zoster 2 (0.3) 1 (0.3)         1 (0.3)
Cellulitis 2 (0.3) 0         2 (0.6)
Recurrent dermatitis 2 (0.3) 1 (0.3)         1 (0.3)
Lichen ruber planus 1 (0.2) 1 (0.3)          0
Total 24 (3.9) 9 (2.8)       15 (5.0)
Table 8B  Cutaneous manifestations in patients with Crohn’s
disese (n=254)
 Total  Male       Female
  n (%)  n (%)         n (%)
Erythema nodosum 14 (5.5) 4 (3.1)       10 (7.8)
Pyoderma gangrenosum   4 (1.6) 3 (2.4)         1 (0.8)
Erythema exsudativum   2 (0.8) 1 (0.8)         1 (0.8)
multiforme
Erythroderma   2 (0.8) 1 (0.8)         1 (0.8)
Stevens Johnson syndrome   1 (0.4) 0         1 (0.8)
Psoriasis   1 (0.4) 0         1 (0.8)
Eczema   1 (0.4) 0         1 (0.8)
Recurrent dermatitis   1 (0.4) 0         1 (0.8)
Total 26 (10.2) 9 (7.2)       17 (13.2)
Table 9  Ocular manifestations in IBD patients
           Total  Anterior      Conjunctivitis       Scleritis
           n (%)        uveitis n (%) n (%)            n (%)
Ulcerative colitis
Total (n=619)         20* (3.2)     6 (1.0)            9 (1.5)          4 (0.7)
Male (n=317)           4 (1.3)     1 (0.3)            3 (1.0)          1 (0.3)
Female (n=302)         16 (5.3)     5 (1.7)            6 (2.0)          3 (1.0)
Crohn’s disease
Total (n=254)           8 (3.1)     4 (1.6)            4 (1.6)          1 (0.4)
Male (n=125)           2 (1.6)     1 (0.8)            0          1 (0.8)
Female (n=129)           6 (4.7)     3 (2.3)            4 (3.1)          0
*One orbital pseudotumor was observed in a young female
UC patient.
Table 10A  Hematological manifestations in patients with
ulcerative colitis
  Total   Male          Female
   n (%)    n (%)            n (%)
Iron deficieny anaemia 159 (25.9) 62 (19.6)       97 (32.1)
Chronic anaemia   59 (9.6) 34 (10.7)       25 (8.3)
Macrocytic anaemia   24 (3.9) 15 (4.7)          9 (3.0)
AIHA     4 (0.6)   2 (0.6)          2 (0.6)
Non-Hodgkin lymphoma     1 (0.2)   1 (0.3)           0
CML     1 (0.2)   1 (0.3)           0
Chronic myeloproliferative disease   1 (0.2)   0          1 (0.3)
Leukemoid reaction     1 (0.2)   0          1 (0.3)
Methaemoglobinaemia     1 (0.2)   0          1 (0.3)
Total 260 (42.0) 90 (28.4)    170 (56.3)
AIHA: autoimmune hemolytic anaemia, CML: chronic myeloid
leukaemia.
Lakatos L et al.EIM in IBD          2303
Table 10B  Hematological manifestations in patients with
Crohn’s disease
      Total     Male  Female
       n (%)     n (%)    n (%)
Iron deficieny anaemia     91 (35.8)   40 (32.0) 51 (39.5)
Chronic anaemia     45 (17.7)   23 (18.4) 22 (17.1)
Macrocytic anaemia     11 (4.3)     6 (4.8)   5 (3.9)
Chronic myeloproliferative   1 (0.4)     0   1 (0.8)
disease
Leukopenia       1 (0.4)     0   1 (0.8)
ITP       1 (0.4)     0   1 (0.8)
Total   150 (59.1)   69 (55.2) 81 (62.8)
ITP: immune thrombocytopenic purpura
Table 10C  Association between hematological complications
and location and disease behaviour in Crohn’s disease patients
      Iron deficieny            Chronic Macrocytic
      anaemia n (%)       anaemia n (%)    anaemia n (%)
Location
L1 (n=60)           17 (28.3)   9 (15.0)     3 (5.0)
L2 (n=81)           22 (27.2)   9 (11.1)     2 (2.5)
L3 (n=113)           42 (37.2) 27 (23.9)     6 (5.3)
Behaviour
B1 (n=87)           27 (31.0) 10 (11.4)     2 (2.3)
B2 (n=62)           23 (37.1) 12 (19.4)     3 (4.8)
B3 (n=105)           41 (39.0) 23 (21.9)     6 (5.7)
      Thromboembolic complication was observed in 11 CD and
8 UC patients (Table 11.). Male predominance was observed in
UC, while it was more frequent in women with CD, 1/15 (6.3 %)
patient was positive for factor V Leiden mutation.
      4.5 % of all IBD patients had multiple major extraintestinal
diseases, three-fold more frequent in patients with CD than in
patients with UC (9.1 % vs 3.1 %, P<0.001, Table 12.). Rare
complications are summarized in Table 13. A relatively high
number of glomerulonephritis was worth mentioning.
Table 11  Thromboembolic complications in patients with IBD
          Ulcerative colitis          Crohn’s disease
Number of patients (%) 11/619 (1.8) 8/254 (3.1)
Male/female 9/2 2/6
Location Proctitis: 0 L1: 3
Left sided colitis: 6 L2: 1
Pancolitis: 5 L3: 4
Behaviour of CD           - B1: 0
B2: 2
B3: 6
Place of thromboembolism
    Lower extremity thrombosis           8 4
    Pulmonary embolism           1 0
    Lower extremity thrombosis           2 3
    complicated by
    pulmonary embolism
    Splenic vein thrombosis           0 1
Table 12  Prevalence of multiple extraintestinal diseases
          Total  n         Ulcerative colitis n       Crohn’s disease n
Two 27        14      13
Three 14           5         9
Four   1           0         1
Total      42/873 (4.5%)          19/619 (3.1%)                  23/254 (9.3%)
Table 13  Extraintestinal manifestations in IBD affecting other
organ systems
Total          Ulcerative            Crohn’s
n (%)          colitis n (%)      disease n (%)
Glomerulonephritis 3 (0.4) 1 (0.2) 2 (0.8)
Asthma bronchiale 7 (0.8) 4 (0.6) 3 (1.2)
Chronic pancreatitis 4 (0.5) 3 (0.5) 1 (0.4)
Acute pancreatitis 2 (0.2) 1 (0.2) 1 (0.4)
Celiac disease 2 (0.2) 1 (0.2) 1 (0.4)
Thyreoiditis 2 (0.2) 2 (0.3) 0
SLE 2 (0.2) 1 (0.2) 1 (0.4)
SLE: systemic lupus erythematodes.
DISCUSSION
It is difficult to define the true prevalence of EIMs in IBD. If
one was counting only major EIMs with common immunogenetic
background the prevalence was about 20-25 %[1,5,8,17,18].
However, if all possible secondary systemic effects and/or
complications of therapy are also included, then almost all
patients will have “extra-intestinal manifestations”. Prevalence
may vary depending on the actual geographic area, IBD
population, location and duration of the disease, medication
and diagnostic accuracy.
     Only few large cohort follow-up data are available on the
prevalence of EIMs in IBD. The study of Greenstein et al. was
one of the first reports[8]. Farmer et al.[19] reported a prevalence
of 16.7 % during a 13-year follow-up study. EIMs were more
prevalent in patients with colonic involvement or previous
operations. In the Swedish epidemiology study Monsen et al.[20]
excluded arthralgia, stomatitis and episcleritis from the EIMs.
More recently, Jiang and Cui[21] analyzed the data of 10218
ulcerative colitis cases in China. The frequency of EIMs was
6.1 %, however no further data were available about the type
of EIM. Bernstein et al.[22] investigated the prevalence of five
“major” EIMs (iritis/uveis, PSC, pyoderma gangrenosum,
erythema nodosum and ankylosing spondylitis) with the help
of the University of Manitoba IBD Database in IBD patients
with a disease history of at least 10 years. They found a single
EIM prevalence of 6.2 %, which was one of the lowest rates
reported. However, peripheral arthropathies were excluded
from their study. There is undoubtedly a debate with the
diagnosis of peripheral arthopathy, as it is sometimes difficult
to distinguish arthropathy from arthralgia, especially in
retrospective studies. In contrast, it is one of the most typical
EIMs, observed in a high frequency of the patients. Excluding
peripheral arthropathy from EIMs in one study and including
it in another make the data difficult to compare. The reported
overall EIM prevalence of 21.3 % in our study is in
concordance with previous studies. The overall prevalence of
EIMs was higher in patients with a longer disease history, but
age at presentation did not affect the prevalence of EIMs.
      There were gender predilections. EIMs were more frequent
in femal pateints compared to males, which may support the
hypothesis that autoimmune diseases are more common in
female subjects.
    The role of genetic factors has been implicated in the
pathogenesis of IBD and EIMs[8-11]. In our study we investigated
the familial occurrence in IBD. Positive family history was
four times more frequent in CD compared to UC. The frequencies
of joint and ocular manifestations were higher in patients with
familial UC. Others have suggested high concordance of the
occurrence of EIMs in affected siblings with IBD[23].
     Previous studies have suggested multiple extraintestinal
diseases[8,22] with certain genetic associations[10,23]. We found
multiple extraintestinal diseases in 4.5 % of IBD patients, more
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common in patients with CD. The most frequent associations
were co-existing ocular, cutaneous and joint (type 1 arthritis)
manifestations. The Canadian study reported multiple
extraintestinl disease in only 0.3 % of all patients[22], however
the rate of multiple EIMs was comparable to our results in
most studies[17, 19].
Relation of EIMs with  type, location and behaviour of IBD
Type of IBD  Overall EIMs were more frequent in patients
with CD than in patients with UC, in concordance with previous
studies[8,24] with the exception of ocular manifestations and PSC.
These two EIMs were equally prevalent in CD and UC (both
occurred approximately in 3 % of the patiens) in concordance
with previous data[10,16,25].
Location of IBD  In UC EIMs were thought to be more
prevalent in extensive disease[5], but there were some
contradiction in the literature[13]. In our study the rate of EIMs
increased with the increasing extent of the disease. In CD it
was generally accepted, that some EIMs were associated with
colonic (e.g. peripheral arthropathy) others with small bowel
(e.g. cholelithiasis) location[8,19]. We also found that type-1
arthritis was twice as frequent in patients with colonic or
ileocolonic disease compared to patients with only ileal disease.
The difference was smaller compared to patients with axial
arthritis and disappeared in patients type 2 arthritis. The
prevalences of cutaneous, ocular and hepatobiliary manifestations
were not associated with location.
Behaviour of CD  We did not find data in the literature about
the relation of EIMs and the behaviour of CD, according to
the Vienna classification. Earlier studies have suggested that
EIMs tended to associate with perianal (=penetrating)
disease[26]. We found a higher rate of joint complications in
stricturing and penetrating disease than in non-stricturing non
penetrating form. All but one ocular disease developed in
patients with penetrating disease, but the rate of other
complications was similar in the three groups.
Extraintestinal manifestations according to affected organs
Arthritis is the most common EIM in IBD  IBD related
arthropaties were originally classified as axial and peripheral
arthritides. Orchard et al. subdivided the peripheral disease
into type 1 (large joint, pauciarticular, parallels with the course
of IBD) and type-2 (small joint, polyarticular, the course
independent of IBD) arthritides[13]. In our study joint
manifestations were more frequently seen in patients with CD,
first of all with the higher prevalence of axial and type-1 arthritis
in these patients. Type-1 arthritis was more frequent in patients
with stenosing and penetrating disease compared to patients
with non-stenosing non-penetrating disease behaviour. In
patients with penetrating disease bacterial infections could
explain the high prevalence, the reason for the high prevalence
in patients with stenosing disease is not clear, perhaps it has a
genetic background.
Hepatobiliary complications  PSC was diagnosed in 1.6 %
in UC and even more infrequently in CD. When small duct
PSC was included, the overall prevalence was 2.9-3.2 % in
both diseases, in concordance with the majority of previous
reports (2.4-11 %)[15,16,27]. PSC was a precancerosus condition
with increased risk for cholangiocarcinoma and colorectal
cancer[28]. In this study 3 patients with PSC and one patient
with small duct cholangitis developed colorectal cancer and
one PSC patient developed cholangiocarcinoma, which
supports a role for more intensive follow-up in these subgroups
of patients.
      The cause of elevated LFT was found to be steatosis and/or
steatohepatitis, reported in 6.3 % in UC and in 4 % in CD in
previous studies[29,30]. An Italian study found that 12 % of the
474 asymptomatic IBD patients had hepatobiliary disease[31].
In non-selected or operated UC patients the prevalence of
steatosis could be as high as 15-45 %[16,32,33]. In our study the
rate of NAFLD was twice as high in CD than in UC, otherwise
our data are in concordance with the data of previous studies.
Several cutaneous diseases were diagnosed, 14 were classified
as EIM. Cutaneous manifestations were more frequent in CD
and in female patients. The prevalence of erythema nodosum
and pyoderma gangrenosum was in the range previously
reported[10,34,35] with very few psoriasis cases.
      Ocular complications were equally frequent in both diseases
with increased prevalence in women. Anterior uveitis was
found at a frequency as previously reported[8,10,22]. We found one
orbital pseudotumour in a young woman with severe ulcerative
pancolitis. Ocular manifestations occurred mostly in the early
few years after diagnosis. Pancolitis patients with UC were
more liable to develop ocular manifestations compared to other
locations. Ocular manifestations did frequently occur together
with other (joint or cutaneous) extraintestinal diseases.
Haematological complications  Iron deficiency anaemia is
the most frequent hematological manifestation. In most of the
cases its course ran parallel to the course of the intestinal
disease. “Chronic anaemia” that occurs in inflammatory
conditions and tumours was mostly apparent in severe,
refractory cases and resolved only slowly after remission.
Macrocytic anaemia was more frequent in patients with ileal
and penetrating/stricturing disease than in patients with colonic
involvement or non-stricturing non-penetrating disease. It was
less frequent since preventive folate supplementation has been
introduced in patients receiving sulfasalazine treatment.
      Autoimmune haemolytic anaemia (AIHA) rarely complicates
IBD, the reported prevalence rates were between 0.2 % and
1.7 %. Our observed rate (0.6 %) correlated with the previous
data. In concordance with other studies AIHA occurred in
patients with extensive colitis. In most of the cases AIHA could
be treated successfully with steroids and/or immunosuppressive
drugs[36]. In our study one patient required splenectomy, and
in another case haemolysis subsided only after colectomy.
    Increased risk of lymphoma has been reported in IBD,
especially in patients receiving immunosupressives, but data
were conflicting[37,38]. Our data do not support the notion of
increased risk in these patients. In our series one 76-year old
male UC patient with left sided colitis developed a high grade
B-cell lymphoma in the rectum, but he did not receive
immunosuppressive therapy. ITP might be true EIM,
methaemoglobinaemia was associated with high dose
sulfasalazine treatment, leukaemoid reaction was seen in a
fulminant relapse.
    Hypercoagulability was thought to be involved in the
pathogenesis of IBD[39-41], and increased risk of thromboembolic
complications (1-6 %) has been reported in IBD[42]. The
prevalence of prothrombotic inherited and/or acquired
coagulation abnormalities in patients with IBD remains
controversial. Genetic thrombophilia with deficiencies in some
coagulation inhibitors (antithrombin, proteins C and S),
acquired thrombophilia due to inflammation, antiphospholipid
syndrome and mutations of factor V Leiden and recently other
genes involved in thrombogenesis (prothrombin mutation
20210A or factor V fV4070G polymorphism) have been
described[39,43]. The most common cause of hypercoagulability
status in Europe is resistance to activated protein C (APC).
Resistance to APC and mutations that cause APC resistance
(mainly factor V Leiden) have been of particular interest[42,43].
Some studies reported increased frequency of Leiden mutation
in IBD[42], however others found that Leiden mutation was
associated with thromboembolism with (14.3 %) or without
IBD (15.5 %) but not with IBD (0 % and controls 3.6 %)
itself [39,44]. In our study Leiden mutation was infrequent in
IBD patients with thrombosis. The frequency was the same
Lakatos L et al.EIM in IBD          2305
that as observed in normal Hungarian population without
thrombosis (5.26 %)[45]. Most thromboembolic episodes
developed in the lower extremities, in some patient with
pulmonary embolism as a complication. Thrombosis of the
splenic vein occurred in one young female CD patient with
ileocolonic disease.
Other EIMs  Glomerulonephritis is a rare complication in
IBD. Only case reports could be found in the literature[46].
Deposition of immune-complexes is thought to be involved in
the pathogenesis. Finding 3 patients (1 UC and 2 CD) in this
series was an unexpected high number. Histology revealed IgA
nephropathy, membranous glomerulonephritis and focal
glomerulosclerosis. Ductal changes suggesting chronic
pancreatitis were common in IBD[47]. Our two pancreatitis cases
developed in patients taking azathioprine.
     In conclusion, in IBD a variety of EIMs may occur during
the course of the disease affecting several organ systems. In
Hungarian IBD patients, major EIMs develop in concordance
with previous European data in approximately one fifth of the
patients. The high number of EIMs supports a role for complex
follow-up in these patients.
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